Get the Stockscreener App
172.81
2.18%
3.69
After Hours:
172.81
Iqvia Holdings Inc stock is traded at $172.81, with a volume of 1.20M.
It is up +2.18% in the last 24 hours and down -2.07% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$169.12
Open:
$169.19
24h Volume:
1.20M
Relative Volume:
0.62
Market Cap:
$28.84B
Revenue:
$16.63B
Net Income/Loss:
$1.39B
P/E Ratio:
21.42
EPS:
8.0674
Net Cash Flow:
$2.12B
1W Performance:
-0.43%
1M Performance:
-2.07%
6M Performance:
-20.47%
1Y Performance:
+21.00%
1-Day Range:
$169.19
$174.97
1-Week Range:
$168.07
$176.26
52-Week Range:
$134.65
$247.04
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
172.81 | 28.23B | 16.63B | 1.39B | 2.12B | 8.0674 |
TMO
Thermo Fisher Scientific Inc
|
442.00 | 162.90B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
163.86 | 114.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
545.79 | 41.71B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
332.19 | 32.32B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.11 | 31.57B | 7.07B | 1.29B | 993.00M | 4.5355 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
IQVIA (IQV) Fell Despite Strong Fundamentals - Insider Monkey
Mid-Cap Stocks: IQVIA (IQV) and First Citizens (FCNCA) Sell SignalsNews and Statistics - IndexBox
IQVIA Holdings (IQV) Q1 earnings and revenues beat estimates - MSN
IQVIA Holdings stock (US46266C1053): earnings, data growth and what investors watch now - AD HOC NEWS
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - Yahoo Finance
IQVIA Holdings Inc stock (US46266C1053): earnings momentum and AI narrative draw fresh attention - AD HOC NEWS
Catholic Responsible Investments Equity Index Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
Is There Now An Opportunity In IQVIA Holdings Inc. (NYSE:IQV)? - Moomoo
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Will IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative? - Yahoo Finance
IQVIA Holdings earnings preview: What to expect - MSN
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $245 - Moomoo
IQVIA Holdings stock (US46266C1053): Expands AI-powered biosimilars deal with Kexing Biopharm - AD HOC NEWS
IQVIA Holdings, Inc. Common Stock (NY: IQV - FinancialContent
IQVIA expands collaboration with Kexing Biopharm on biosimilars - Investing.com UK
Why (IQV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
IQVIA expands collaboration with Kexing Biopharm on biosimilars By Investing.com - Investing.com Nigeria
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AI-powered trials to speed global biosimilar drugs in IQVIA-Kexing pact - Stock Titan
IQVIA Holdings stock (US46266C1053): Global leader in healthcare data analytics - AD HOC NEWS
Assessing IQVIA Holdings (IQV) Valuation After Expanded AI Clinical Trial Collaboration With Kexing Biopharm - Sahm
IQVIA Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Nigeria
IQVIA Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges By Investing.com - Investing.com South Africa
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges - Investing.com
IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MSN
IQVIA Holdings | 4: Statement of changes in beneficial ownership of securities-Director GOGGINS COLLEEN A - Moomoo
IQVIA (NYSE: IQV) director granted 171 deferred shares at $178.64 - Stock Titan
IQVIA (NYSE: IQV) director Colleen Goggins receives 214 Deferred Shares grant - Stock Titan
IQVIA (NYSE: IQV) director Jim Fasano receives 228 deferred share award - Stock Titan
IQVIA (NYSE: IQV) director awarded 185 deferred shares with 1:1 common conversion - Stock Titan
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why is Larry Robbins Bullish on IQVIA Holdings (IQV) Amid Market Volatility - Kavout
IQVIA Holdings Inc. (IQV): Larry Robbins Is Bullish on This Stock - Insider Monkey
Why IQVIA Holdings (IQV) Is Up 12.8% After Q1 Beat and Bigger Buyback Plan – And What's Next - Sahm
Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China - GlobeNewswire Inc.
IQVIA Holdings, Inc. (IQV) Stock Analysis: Robust Growth Potential With A 27.92% Upside - DirectorsTalk Interviews
IQVIA Q1 Earnings Call Highlights - sharewise.com
Here's why you should retain IQV stock in your portfolio now - MSN
IQVIA Holdings stock (US46266C1053): Data?driven healthcare analytics in focus for US investors - AD HOC NEWS
IQVIA board authorizes additional $2B in share repurchases - MSN
IQVIA Expands Share Repurchase Authorization by $2 Billion - The Globe and Mail
BMO Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $210 - Moomoo
IQVIA Holdings Inc. (NYSE:IQV) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
IQVIA Holdings | 8-K: Current report - Moomoo
Earnings Update: IQVIA Holdings Inc. (NYSE:IQV) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
IQVIA Increases Share Repurchase Authorization by $2 Billion, Bringing Total to $3.2 Billion 1 - Minichart
Artificial Intelligence in Epidemiology Market Is Going - openPR.com
Mitsubishi UFJ Asset Management Co. Ltd. Grows Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization - The National Law Review
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):